End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
56.9 CNY | -0.14% | -0.61% | +15.77% |
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.77% | 14.09B | C+ | ||
+32.95% | 700B | C+ | ||
+26.51% | 569B | B | ||
-4.97% | 358B | C+ | ||
+18.83% | 330B | B- | ||
+3.54% | 287B | C+ | ||
+15.70% | 236B | B+ | ||
+6.68% | 202B | B- | ||
-9.08% | 197B | A+ | ||
+6.70% | 161B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 000538 Stock
- Ratings Yunnan Baiyao Group Co.,Ltd